The National Healthcare Security Administration (NHSA) has issued a notification regarding the review and correction of results related to drugs on the preliminary formal review list of the National Reimbursement Drug List (NRDL). This update follows feedback collected from August 7 to 13, 2024.
The revised list now includes 249 drugs previously excluded from the NRDL. Notably, three new exclusive Western medicines—megestrol, terbutaline, and sulbactam—have been added, all of which are domestically manufactured. Importantly, there have been no changes to the existing NRDL drugs.- Flcube.com
